Skip to main content
. Author manuscript; available in PMC: 2021 Dec 15.
Published in final edited form as: Circulation. 2020 Oct 2;142(24):2299–2311. doi: 10.1161/CIRCULATIONAHA.120.049981

Table 4.

Absolute and relative change in thoracic atherosclerotic plaque volume from before starting an immune checkpoint inhibitor (Scan 0-Scan 1) to after starting an immune checkpoint inhibitor (Scan 1 to Scan 2).

Scan 0 - Scan 1 Scan 1 – Scan 2 * P Value
Absolute change Indexed change per year, mm3/year Total plaque volume 13.8 (−240, 122) 103 (0, 511) 0.02
Non-calcified plaque volume −18.2 (−274, 57) 53 (0, 382) 0.02
Relative change Indexed change per year, %/year Total plaque volume 2.1% (−13.0%, 18.6%) 6.7% (2.2%, 28.1%) 0.17
Non-calcified plaque volume −2.3% (−14.0%, 12.7%) 5.3% (1.4%, 40.1%) 0.14

Values are median (interquartile range).

*

P: Wilcoxon signed-rank test comparing annual rate of progression in plaque volume from scan 0 to scan 1 and from scan 1 to scan 2. The relative change is the change in the plaque volume per year.